Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
obstructive sleep apnea, FDA
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
FDA approves sleep apnea drug
New York Attorney General Letitia James on Friday released what she described as “shocking and disturbing” footage from body-worn cameras of correctional officers showing the fatal beating of an inmate at the Marcy Correctional Facility in upstate New York.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
1h
Health Beat: Sleep disorders in the Hispanic community
According to the Hispanic Community Health Study, 14% of Hispanic men and 6% of Hispanic women have sleep apnea. With so many ...
6d
New device to treat sleep apnea was life-changing for NMHS patient
For those who have tried unsuccessfully to use a CPAP machine to treat sleep apnea, the Inspire implant is a breakthrough ...
UPI News on MSN
11d
Sleep apnea might change brain, speed aging
Sleep apnea is known to wreak havoc on the body and also appears to have direct effects on brain health, a new study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Trump endorses Johnson
Tony-winning actress dies
Iran confirms arrest
Blood clot during pregnancy
15 bodies found in Mexico
Dress code issue resolved
Parents of shooter jailed
Moon rock destroyed in fire
Ethiopia accident
Court upholds $5M award
World population estimate
Protection process begins
2 men found dead in forest
S. Korea seeks Yoon's arrest
Daniels sets NFL record
Announces new aid for UKR
Halifax airport delays
5 charged in Payne's death
Airstrike near Damascus
Hackers target extensions
Flood warnings in effect
I-80 reopens after repairs
Ex-FSU players sue coach
Signs deal with Ukraine
Pending home sales rise
Azerbaijan accuses Russia
SpaceX's final 2024 missions
UKR, RU swap prisoners
Completes prostate surgery
World leaders pay tribute
South Korea orders probe
Related topics
Zepbound
Weight loss drug
Tirzepatide
U.S. Customs and Border Protection
Feedback